바이오인

 

 

Singapore’s vision is to be the Biopolis of Asia, a leading international biomedical sciences cluster, where companies can impact global health by achieving excellence and synergies across R&D, manufacturing and headquarter activities.

The global biomedical sciences industry is confronted with the need to improve R&D productivity and address unmet healthcare needs in fast-growing regions such as Asia.At the same time, companies need to navigate Asia’s complexities and diversity to effectively tap into the region’s markets.

For companies seeking to improve R&D productivity and develop innovative medical solutions for Asia, Singapore presents opportunities to tap into the multidisciplinary capabilities offered by an integrated research network in basic and translational research. Today, more than 7,100 researchers carry out biomedical sciences R&D in more than 50 companies, our universities, and 30 public-sector institutes under the Agency for Science, Technology and Research (A*STAR) and the Ministry of Health (MOH). Collectively, more than S$1.51 billion is spent on biomedical R&D annually.

 

 

....(계속)